The California Institute for Regenerative Medicine (CIRM) recently approved nearly $31 million in funding, further cementing our commitment to advancing the field of regenerative medicine. This substantial investment aims to drive clinical research targeting various cancers and eye diseases.
CIRM’s dedication to fostering innovative treatments is demonstrated through its clinical program, which funds eligible stem cell and gene therapy-based projects at all stages of clinical trial development. With these new awards, CIRM’s clinical portfolio now includes 106 clinical trials.
During CIRM’s April Application Review Subcommittee (ARS) meeting, the following vital projects were approved for funding:
Application | Program Title | Principal Investigator/Institution | Amount |
CLIN2-15282 | RPESC-RPE Therapy for dry Age-related Macular Degeneration | Stern, Jeffrey H – Luxa Biotechnology | $4,009,675 |
CLIN2-15311 | A Phase I/IIa Study to Evaluate the Efficacy of a Gene Therapy with Standard of Care Therapy in Newly Diagnosed High Grade Glioma | Kasahara, Noriyuki – UCSF | $11,807,220 |
CLIN2-15343 | A Phase 1B Study Evaluating the Safety and Efficacy of an Allogenic Cell Therapy in Subjects with Clear Cell Renal Cell Carcinoma (ccRCC) | Le Gall, John – Allogene Therapeutics | $15,000,000 |
These projects are poised to make significant strides in developing new therapies that could revolutionize the treatment landscape for cancer and eye diseases. By supporting these cutting-edge research initiatives, CIRM continues to pave the way for breakthroughs in regenerative medicine.
Stay tuned for updates on the progress of these exciting projects and learn how they are making a difference in healthcare by signing up for our monthly newsletter.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://blog.cirm.ca.gov/2024/06/18/cirms-31-million-boost-for-cancer-and-eye-disease-research/